Peer-influenced content. Sources you trust. No registration required. This is HCN.

OBR OncologyRoche Cancer Immunotherapy Fails Another Trial, Casting Doubt On Emerging Drug Class

In an interim look at the SKYSCRAPER-01 study, investigators found tiragolumab plus atezolizumab didn’t meaningfully slow tumor progression compared to atezolizumab alone in patients with advanced, newly diagnosed non-small cell lung cancer (NSCLC). Tiragolumab has now fallen short in two phase 3 lung cancer trials, having already missed its study objectives in advanced SCLC earlier this year.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form